Method of treating amd in patients refractory to anti-vegf therapy
AssigneeAllergan, Inc.
InventorThomas Conlon Hohman
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods for the treatment of a patient having an ocular conditions such as age-related macular degeneration or diabetic macular edema through administration of a recombinant binding protein comprising an ankyrin repeat domain. In some embodiments, the composition may be administered every 8 weeks to every 16 weeks. In some embodiments, the patient being treated may be refractory to existing anti-VEGF therapies.
Claims24
A method of inhibiting binding between VEGF-Axxx and VEGFR-2, the method comprising the step of administering to a patient in need of such inhibition, at a frequency between 8 weeks and 16 weeks, a dose of about 1 mg to about 4 mg of a recombinant binding protein comprising an ankyrin repeat domain, wherein the ankyrin domain binds VEGF-Axxx with a Kd below 109M.
Dependencies are inferred from the claim text.